May 15 (Reuters) - U.S. legislation that would restrict business with China's BGI, WuXi AppTec and certain other biotech companies on national security grounds will be voted on by a committee in the House of Representatives on Wednesday.

If approved by the House Committee on Oversight and Accountability, the Biosecure Act would still need to be voted on by the full House and Senate before the president could sign it into law. The bill would push U.S. pharmaceutical and healthcare companies to lessen their reliance on Chinese research and manufacturing.

The U.S. Senate Homeland Security and Governmental Affairs committee voted in favor of similar legislation in March.

The latest version of the House bill gives U.S. companies until 2032 to end work with the Chinese firms, news that lifted shares of potentially impacted Chinese companies in trading in Hong Kong earlier this week.

The latest draft also adds WuXi Biologics to a list of company of concern that includes WuXi AppTec, as well as BGI, MGI and Complete Genomics.

Supporters say the legislation is needed to keep Americans' health and genetic information from foreign adversaries, who could weaponize the data. They also say it is dangerous for China to dominate the biotechnology supply chain.

The targeted companies say the proposed legislation is based on false and misleading allegations and would limit competition. They say they do not pose a threat to U.S. national security and that they should not be included in the bill.

The Biosecure Act would bar federal agencies from contracting with biotech companies deemed of concern. It also would prohibit contracts with companies that use those companies' equipment or services.

In 2023, Wuxi Biologics earned about 47% of its 17 billion yuan in annual sales from North America and about 18% from China, according to its annual report.

Two-thirds of WuXi AppTec's revenue came from the U.S. market in the first nine months of 2023, according to an investor.

Complete Genomics - another "company of concern" - is a U.S. founded company, headquartered in San Jose, Calif. It is a subsidiary of China's MGI, a publicly traded global company.

BGI, a leading provider of genetic sequencing services around the world, has said the legislation will drive the company out of the U.S. (Reporting by Karen Freifeld; Editing by Michael Erman)